- Home
- IMMX vs GCV Comparison
IMMX vs GCV Comparison
Compare IMMX & GCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- GCV
- Stock Information
- Founded
- IMMX 2014
- GCV 1988
- Country
- IMMX United States
- GCV United States
- Employees
- IMMX N/A
- GCV N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- GCV Finance/Investors Services
- Sector
- IMMX Health Care
- GCV Finance
- Exchange
- IMMX Nasdaq
- GCV Nasdaq
- Market Cap
- IMMX 82.6M
- GCV 85.1M
- IPO Year
- IMMX 2021
- GCV N/A
- Fundamental
- Price
- IMMX $3.05
- GCV $4.30
- Analyst Decision
- IMMX Strong Buy
- GCV
- Analyst Count
- IMMX 1
- GCV 0
- Target Price
- IMMX $8.00
- GCV N/A
- AVG Volume (30 Days)
- IMMX 453.7K
- GCV 57.9K
- Earning Date
- IMMX 11-11-2025
- GCV 01-01-0001
- Dividend Yield
- IMMX N/A
- GCV 13.04%
- EPS Growth
- IMMX N/A
- GCV N/A
- EPS
- IMMX N/A
- GCV N/A
- Revenue
- IMMX N/A
- GCV N/A
- Revenue This Year
- IMMX N/A
- GCV N/A
- Revenue Next Year
- IMMX N/A
- GCV N/A
- P/E Ratio
- IMMX N/A
- GCV N/A
- Revenue Growth
- IMMX N/A
- GCV N/A
- 52 Week Low
- IMMX $1.34
- GCV $3.15
- 52 Week High
- IMMX $3.20
- GCV $4.58
- Technical
- Relative Strength Index (RSI)
- IMMX 77.89
- GCV 62.18
- Support Level
- IMMX $2.31
- GCV $4.22
- Resistance Level
- IMMX $2.82
- GCV $4.36
- Average True Range (ATR)
- IMMX 0.25
- GCV 0.06
- MACD
- IMMX 0.08
- GCV -0.00
- Stochastic Oscillator
- IMMX 95.41
- GCV 73.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.